Oh Gyu Chul, Lee Hae-Young, Chung Wook Jin, Youn Ho-Joong, Cho Eun-Joo, Sung Ki-Chul, Chae Shung Chull, Yoo Byung-Su, Park Chang Gyu, Hong Soon Jun, Kim Young Kwon, Hong Taek-Jong, Choi Dong-Ju, Hyun Min Su, Ha Jong Won, Kim Young Jo, Ahn Youngkeun, Cho Myeong Chan, Kim Soon-Gil, Shin Jinho, Park Sungha, Sohn Il-Suk, Kim Chong-Jin
Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Division of Cardiovascular Disease, Department of Internal Medicine, Gachon University Gil Hospital, Medical Center, Incheon, Korea.
Clin Hypertens. 2017 Sep 4;23:18. doi: 10.1186/s40885-017-0074-0. eCollection 2017.
Hypertension is a risk factor for coronary heart disease and stroke, and is one of the leading causes of death. Although over a billion people are affected worldwide, only half of them receive adequate treatment. Current guidelines on antihypertensive treatment recommend combination therapy for patients not responding to monotherapy, but as the number of pills increase, patient compliance tends to decrease. As a result, fixed-dose combination drugs with different antihypertensive agents have been developed and widely used in recent years. CCBs have been shown to be better at reducing central blood pressure and arterial stiffness than diuretics. Recent studies have reported that central blood pressure and arterial stiffness are associated with cardiovascular outcomes. This trial aims to compare the efficacy of combination of calcium channel blocker (CCB) or thiazide diuretic with an angiotensin receptor blocker (ARB).
This is a multicenter, double-blinded, active-controlled, phase 4, randomized trial, comparing the antihypertensive effects of losartan/amlodipine and losartan/hydrochlorothiazide in patients unresponsive to treatment with losartan. The primary endpoint is changes in mean sitting systolic blood pressure (msSBP) after 4 weeks of treatment. Secondary endpoints are changes in msSBP, mean 24-h ambulatory mobile blood pressure, mean 24-h ambulatory mobile central SBP, mean 24-h ambulatory carotid-femoral pulse wave velocity, ambulatory augmentation index, and microalbuminuria/proteinuria after 20 weeks of treatment. The sample size will be 119 patients for each group in order to confer enough power to test for non-inferiority regarding the primary outcome.
The investigators aim to prove that combination of a CCB with ARB shows non-inferiority in lowering blood pressure compared with a combination of thiazide diuretic and ARB. We also hope to distinguish the subset of patients that are more responsive to certain types of combination drugs. The results of this study should aid physicians in selecting appropriate combination regimens to treat hypertension in certain populations.
ClinicalTrials.gov NCT02294539. Registered 12 November 2014.
高血压是冠心病和中风的危险因素,也是主要死因之一。尽管全球有超过十亿人受其影响,但只有一半的人得到了充分治疗。当前的抗高血压治疗指南建议,对于单药治疗无效的患者采用联合治疗,但随着药片数量增加,患者的依从性往往会下降。因此,近年来已开发并广泛使用了含有不同抗高血压药物的固定剂量复方制剂。与利尿剂相比,钙通道阻滞剂(CCB)在降低中心血压和动脉僵硬度方面表现更佳。近期研究报告称,中心血压和动脉僵硬度与心血管疾病转归相关。本试验旨在比较钙通道阻滞剂(CCB)或噻嗪类利尿剂与血管紧张素受体阻滞剂(ARB)联合用药的疗效。
这是一项多中心、双盲、活性药物对照的4期随机试验,比较氯沙坦/氨氯地平和氯沙坦/氢氯噻嗪对氯沙坦治疗无效患者的降压效果。主要终点是治疗4周后坐位平均收缩压(msSBP)的变化。次要终点是治疗20周后msSBP、24小时动态平均血压、24小时动态平均中心收缩压、24小时动态颈股脉搏波速度、动态增强指数以及微量白蛋白尿/蛋白尿的变化。每组样本量为119例患者,以便有足够的检验效能来检测主要结局的非劣效性。
研究者旨在证明CCB与ARB联合用药在降低血压方面与噻嗪类利尿剂和ARB联合用药相比具有非劣效性。我们还希望区分出对某些类型复方药物反应更佳的患者亚组。本研究结果应有助于医生为特定人群选择合适的联合治疗方案来治疗高血压。
ClinicalTrials.gov NCT02294539。于2014年11月12日注册。